Literature DB >> 22233609

Thymosin β 4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition.

Sonia Nemolato1, Angelo Restivo, Tiziana Cabras, Pierpaolo Coni, Luigi Zorcolo, Germano Orrù, Mattia Fanari, Flaviana Cau, Clara Gerosa, Daniela Fanni, Irene Messana, Massimo Castagnola, Giuseppe Casula, Gavino Faa.   

Abstract

OBJECTIVE: Thymosin β 4 (Tβ(4)) is a ubiquitous peptide that plays pivotal roles in the cytoskeletal system and in cell differentiation during embryogenesis. Recently, a role for Tβ(4) has been proposed in experimental and human carcinogenesis. This study was aimed at evaluating the correlation between Tβ(4) immunoractivity and colorectal cancer, with particular attemption to tumor cells undergoing epithelial-mesenchymal transition. METHODS AND
RESULTS: 86 intestinal biopsies were retrospectively analyzed including 76 colorectal adenocarcinomas with evident features of epithelial-mesenchymal transition, and 10 samples of normal colorectal mucosa. Paraffin sections were immunostained for Tβ(4) and for E-cadherin. Total RNA was isolated from frozen specimens obtained, at surgery, from the normal colon mucosa, the deeper regions and the superficial tumor regions in four cases of colon cancer. Tβ(4) immunoreactivity was detected in the vast majority (59/76) of colon carcinomas, showing a patchy distribution, with well differentiated areas significantly more reactive than the less differentiated tumor zones. We also noted a zonal pattern in the majority of tumors, characterized by a progressive increase in immunostaining for Tβ(4) from the superficial toward the deepest tumor regions. The strongest expression for Tβ(4) was frequently detected in invading tumor cells with features of epithelial-mesenchymal transition. The increase in reactivity for Tβ(4) matched with a progressive decrease in E-cadherin expression in invading cancer cells. At mRNA level, the differences in Tβ(4) expression between the surrounding colon mucosa and the tumors samples were not significant.
CONCLUSIONS: Our data show that Tβ(4) is expressed in the majority of colon cancers, with preferential immunoreactivity in deep tumor regions. The preferential expression of the peptide and the increase in intensity of the immunostaining at the invasion front suggests a possible link between the peptide and the process of epithelial mesenchymal transition, suggesting a role for Tβ(4) in colorectal cancer invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233609     DOI: 10.4161/cbt.13.4.18691

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  19 in total

1.  The surprising composition of the salivary proteome of preterm human newborn.

Authors:  Massimo Castagnola; Rosanna Inzitari; Chiara Fanali; Federica Iavarone; Alberto Vitali; Claudia Desiderio; Giovanni Vento; Chiara Tirone; Costantino Romagnoli; Tiziana Cabras; Barbara Manconi; Maria Teresa Sanna; Roberto Boi; Elisabetta Pisano; Alessandra Olianas; Mariagiuseppina Pellegrini; Sonia Nemolato; Claus Wilhelm Heizmann; Gavino Faa; Irene Messana
Journal:  Mol Cell Proteomics       Date:  2010-10-13       Impact factor: 5.911

Review 2.  Adamantinomatous craniopharyngioma: advances in proteomic research.

Authors:  Claudia Desiderio; Diana Valeria Rossetti; Massimo Castagnola; Luca Massimi; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2020-07-02       Impact factor: 1.475

3.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

4.  Identification of thymosins β4 and β 10 in paediatric craniopharyngioma cystic fluid.

Authors:  Claudia Desiderio; Claudia Martelli; Diana Valeria Rossetti; Concezio Di Rocco; Luca D'Angelo; Massimo Caldarelli; Gianpiero Tamburrini; Federica Iavarone; Massimo Castagnola; Irene Messana; Tiziana Cabras; Gavino Faa
Journal:  Childs Nerv Syst       Date:  2013-03-17       Impact factor: 1.475

5.  Thymosin β4 cytoplasmic/nuclear translocation as a new marker of cellular stress. A Caco2 case study.

Authors:  Pierpaolo Coni; Monica Piras; Anna Mateddu; Marco Piludu; Germano Orru; Alessandra Scano; Tiziana Cabras; Valentina Piras; Joanna Izabela Lachowicz; Mariusz Jaremko; Gavino Faa; Massimo Castagnola; Giuseppina Pichiri
Journal:  RSC Adv       Date:  2020-03-30       Impact factor: 4.036

6.  Thymosin beta 4 may translocate from the cytoplasm in to the nucleus in HepG2 cells following serum starvation. An ultrastructural study.

Authors:  Marco Piludu; Monica Piras; Giuseppina Pichiri; Pierpaolo Coni; Germano Orrù; Tiziana Cabras; Irene Messana; Gavino Faa; Massimo Castagnola
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

7.  Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Kenneth W Jackson; Victoria J Christiansen; Vivek R Yadav; Robert Silasi-Mansat; Florea Lupu; Vibhudutta Awasthi; Roy R Zhang; Patrick A McKee
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

8.  Cellular trafficking of thymosin beta-4 in HEPG2 cells following serum starvation.

Authors:  Giuseppina Pichiri; Pierpaolo Coni; Sonia Nemolato; Tiziana Cabras; Mattia Umberto Fanari; Alice Sanna; Eliana Di Felice; Irene Messana; Massimo Castagnola; Gavino Faa
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

9.  Thymosin ß4 expression in colorectal polyps and adenomas.

Authors:  Sonia Nemolato; Tiziana Cabras; Angelo Restivo; Luigi Zorcolo; Eliana Di Felice; Daniela Fanni; Clara Gerosa; Irene Messana; Massimo Castagnola; Gavino Faa; Giuseppe Casula
Journal:  Clinics (Sao Paulo)       Date:  2013-09       Impact factor: 2.365

10.  Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma.

Authors:  W Theunissen; D Fanni; S Nemolato; E Di Felice; T Cabras; C Gerosa; P Van Eyken; I Messana; M Castagnola; G Faa
Journal:  Eur J Histochem       Date:  2014-03-11       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.